Recent years are characterized by close attention to diseases, which are often a component of metabolic syndrome (MS). The pathogenetic multifacency of the MS and the clinical heterogeneity of the manifestations of the diseases give the problem of contemporary sound, provides formation of new perspectives on their course and the development of therapies. The promising direction of drug therapy is the use of metabolic drugs. Metabolic therapy has become one of the areas in the treatment of heart failure, therefore the compulsory component of treatment should be drugs that act to stabilize the myocardial metabolism, and the correction of hypoxia and its effects is important for the adaptation of tissues to work in conditions of reduced supply of oxygen. The basis of metabolic therapy is the protection of the myocardium from cardiotoxic action of catecholamines released during physical activity, as well as energy-saving correction of oxidation processes. The purpose of the work was to study the effectiveness of metabolic therapy in sport horses for myocardial dystrophy. In order to assess the influence of metabolic syndrome (MS) on myocardium and the analysis of the effectiveness of metabolic therapy, patients with myocardial dystrophy of horses were selected. According to the results of clinical studies and analysis of indicators of blood of sick horses was divided into two groups: the first included animals that were treated, the second - which were not treated. From the control group of horses of two animals at 8 and 9 days was excluded from research due to complications due to the development of metabolic syndrome. Metabolic therapy in sports horse patients with myocardial dystrophy contributed to the restoration of work capacity, normalization of the frequency of respiration and pulse, reduction of the incidence of cardiac arrhythmias, arrhythmias and valve regurgitation, restoration of hydration (reduction of total protein content) and renal function (reduction of urea and creatinine concentrations), normalization carbohydrate metabolism, restoration and stabilization of membranes of cardiomyocytes (reduction of lactate concentration and activity of AST, СK, СK-MB, LDH, LDH-1), and consequently jay complication and development of metabolic dysfunction. In animals of the control group, which were not treated, complications of myocardial dystrophy in the form of a metabolic syndrome developed, which were manifested by an increase in the percentage of animals with reduced capacity for work, tachypnea and tachycardia, an increase in the incidence of cardiac noise, arrhythmias and valve regurgitation, the development of dehydration (increase in total protein content), violation renal function (increased urea concentration and creatinine), development of cardiomyocyte cytolysis syndrome (increased lactate and ac activity of the AST, CК, СК-MB, LDH, LDH-1).